1. Participant Flow



2. Baseline Characteristics

Baseline Characteristics		**Groups**	
Demographic data:		**Control group**	**Experimental group**
Age (mean ± SD)		*33.6 ± 6.3*	*33.2 ± 6*
Sex; count (%)			
	Males	*12 (30%)*	*18 (45%)*
	Females	*28 (70%)*	*22 (55%)*
Ethnicity		*Asian*	*Asian*
Clinical Characteristics:			
Pre-operative pain score (mean ± SD)		*13.1 ± 17.4*	*18.1 ± 12.4*
Teeth included in the study; count (%)			
	Maxillary Central Incisor	*4 (10%)*	*2 (5%)*
	Maxillary Lateral Incisor	*4 (10%)*	*4 (10%)*
	Maxillary Canine	*8 (20%)*	*7 (17.5%)*
	Maxillary 2nd Premolar	*6 (15%)*	*14 (35%)*
	Mandibular Central Incisor		
	Mandibular Lateral Incisor	*3 (7.5%)*	
	Mandibular Canine	*1 (2.5%)*	*2 (5%)*
	Mandibular 1st Premolar	*4 (10%)*	*5 (12.5%)*
	Mandibular 2nd Premolar	*10 (25%)*	*6 (15%)*

3. OUTCOME MEASURES

PRIMARY OUTCOME (1a):

Difference of mean pain scores between the groups; without exclusion of patients who took analgesics

Interval	N (33)	Group I Mean Pain Score (min – max)	N (35)	Group II Mean Pain Score (min – max)	Mean Difference (P-value)
Pre-op		14.7 ± 18.3 (1 – 90)		20.6 ± 17.3 (2 – 50)	*-5.87 (0.053*)*
4 hours		11.8 ± 18.7 (0 – 70)		8.8 ± 11.1 (0 – 43)	*2.96 (0.329)*
12 hours		9.4 ± 16.7 (0 – 50)		10.3 ± 13.3 (0 – 49)	*-0.92 (0.764)*
Day 2		3.5 ± 7.7 (0 – 30)		5.1 ± 9.2 (0 – 30)	*-1.57 (0.605)*
Day 3		2.6 ± 6.4 (0 – 30)		3.4 ± 6.8 (0 – 25)	*-0.82 (0.786)*
Day 4		1.9 ± 4.7 (0 – 20)		2.7 ± 7.3 (0 – 30)	*-0.72 (0.813)*

** Significant at 0.05*

PRIMARY OUTCOME (1b):

Difference of mean pain scores between the groups; with exclusion of patients who took analgesics

Interval	N	Group I Mean Pain Score (min – max)	N	Group II Mean Pain Score (min – max)	Mean Difference (P-value)
4 hours	26	3.1 ± 5.3 (0 – 23)	32	6.6 ± 8.3 (0 – 24)	*-3.49 (0.146)*
12 hours	26	1.4 ± 3.6 (0 – 15)	26	4.3 ± 6.6 (0 – 20)	*-2.92 (0.245)*
Day 2	26	0.5 ± 1.4 (0 – 5)	25	1.4 ± 3.0 (0 – 10)	*-0.94 (0.712)*
Day 3	26	0.8 ± 2.2 (0 – 9)	25	1.4 ± 3.5 (0 – 12)	*-0.63 (0.803)*
Day 4	26	0.6 ± 1.2 (0 – 9)	24	0.5 ± 2.0 (0 – 10)	*0.08 (0.976)*

SECONDARY OUTCOME (1):

Incidence of flare-up

Time Interval	Caoh (%) N= 33	Propolis (%) N= 35	Total (%)
4 hours	4 (5.9%)	1 (1.5%)	*5 (7.4%)*
12 hours	0 (0%)	4 (5.9%)	*4 (5.9%)*
Day 2	0 (0%)	1 (1.5%)	*1 (1.5%)*
Day 3	0 (0%)	0 (0%)	*0 (0%)*
Day 4	0 (0%)	0 (0%)	*0 (0%)*
Total (%)	*4 (5.9%)*	*6 (8.9%)*	*10 (14.8%)*

SECONDARY OUTCOME (2a):

Comparison of pain scores between the various time intervals; without exclusion of patients who took analgesics

Time	**Pre-op**	**4 hours**	**12 hours**	**Day 2**	**Day 3**	**Day 4**
Pre-op	C →	2.97 (0.334)	5.30 (0.085)	11.18 (0.000**)	12.12 (0.000**)	12.79 (0.000**)
4 hours	11.80 (0.000**)	C → ← E	2.33 (0.448)	8.21 (0.008**)	9.15 (0.003**)	9.82 (0.001**)
12 hours	10.26 (0.001**)	-1.54 (0.605)	C → ← E	5.88 (0.056*)	6.82 (0.27)	7.84 (0.015**)
Day 2	15.49 (0.000**)	3.69 (0.217)	5.23 (0.80)	C → ← E	0.94 (0.760)	1.61 (0.601)
Day 3	17.17 (0.000**)	5.37 (0.72)	6.91 (0.21)	1.69 (0.574)	C → ← E	0.67 (0.828)
Day 4	17.94 (0.000**)	6.14 (0.40)	7.69 (0.10)	2.46 (0.410)	0.77 (0.796)	← E

*** significant at 0.01, * significant at 0.05*

C→ = control group values, ←E = Experimental group values

SECONDARY OUTCOME (2b):

Comparison of pain scores between the various time intervals; with exclusion of patients who took analgesics

Time	**Pre-op**	**4 hours**	**12 hours**	**Day 2**	**Day 3**	**Day 4**
Pre-op	C →	11.65 (0.000**)	13.34 (0.000**)	14.27 (0.000**)	13.92 (0.000**)	14.15 (0.000**)
4 hours	14.04 (0.000**)	C → ← E	1.69 (0.501)	2.62 (0.298)	2.27 (0.367)	2.5 (0.320)
12 hours	16.29 (0.000**)	2.25 (0.346)	C → ← E	0.92 (0.713)	0.58 (0.818)	0.81 (0.748)
Day 2	19.20 (0.000**)	5.16 (0.33)	2.91 (0.252)	C → ← E	-0.35 (0.890)	-0.12 (0.963)
Day 3	19.16 (0.000**)	5.12 (0.035*)	2.87 (0.259)	-0.4 (0.988)	C → ← E	0.23 (0.927)
Day 4	20.10 (0.000**)	6.06 (0.014**)	0.381 (0.138)	0.90 (0.728)	0.94 (0.717)	← E

*** significant difference at 0.01, * significant at 0.05*

C→ = Control group values, ←E = Experimental group values

OTHER OUTCOME (1a):

Quantitative analysis of pain score among genders

Interval	**N**	**Males Mean Pain Score (min – max)**	**N**	**Females Mean Pain Score (min – max)**	**Mean Difference (P-value)**
4 hours	25	9.8 ± 11.9 (0 – 40)	43	10.4 ± 16.9 (0 – 70)	*-0.6 (0.412)*
12 hours	25	11.6 ± 14.5 (0 – 49)	43	8.8 ± 15.2 (0 – 50)	*2.8 (0.94)*
Day 2	25	7.8 ± 11 (0 – 30)	43	2.3 ± 5.8 (0 – 25)	*5.5 (0.035*)*
Day 3	25	5.8 ± 8.9 (0 – 30)	43	1.40 ± 4 (0 – 20)	*4.4 (0.023*)*
Day 4	25	5 ± 9.2 (0 – 30)	43	0.70 ± 2.1 (0 – 9)	*4.3 (0.020*)*

** Significant at 0.05*

OTHER OUTCOME (1b):

The qualitative analysis of pain among genders

Time Interval	**Gender**	**No or mild pain (%)**	**Moderate pain (%)**	**Severe pain (%)**	**Total**
4 hours	*Male*	21 (30.9%)	4 (5.9%)	0	68
	Female	37 (54.4%)	3 (4.4%)	3 (4.4%)	
12 hours	*Male*	19 (27.9%)	6 (8.8%)	0	68
	Female	36 (52.9%	5 (7.4%)	2 (2.9%)	
Day 2	*Male*	21 (30.9%)	4 (5.9%)	0	68
	Female	41 (60.3%)	2 (2.9%)	0	
Day 3	*Male*	23 (33.8%)	2 (2.9%)	0	68
	Female	43 (63.2%)	0	0	
Day 4	*Male*	23 (33.8%)	2 (2.9%)	0	68
	Female	43 (63.2%)	0	0	

OTHER OUTCOME (2a):

The difference of pain scores between the age groups

Time Interval	20 – 24 (N=6)	25- 29 (N= 10)	30 – 34 (N= 17)	35 – 40 (N= 35)	P - value
	MEAN RANK				
4 hours	32.9	44.7	37.5	30.3	*0.15*
12 hours	30.8	36.5	40.6	31.5	*0.36*
Day 2	24	43.1	35.3	33.4	*0.13*
Day 3	30.7	33.2	31.3	37	*0.55*
Day 4	27	33.7	30.5	37.9	*0.17*

OTHER OUTCOME (2b):

The types of pain prevalent among age groups

Time	Pain severity	20 to 24 (%)	25 to 29 (%)	30 to 34 (%)	35 to 40 (%)
4 hours	*No or mild*	6 (9%)	8 (12%)	13 (19%)	31 (46%)
	Mod	0	2 (3%)	2 (3%)	3 (4%)
	Severe	0	0	2 (3%)	1 (1.5%)
12 hours	*No or mild*	5 (7%)	7 (10%)	13 (19%)	30 (44%)
	Moderate	1 (1.5%)	3 (4%)	3 (4%)	4 (6%)
	Severe	0	0	1 (1.5%)	1 (1.5%)
Day 2	*No or mild*	6 (9%)	7 (10%)	16 (23.5%)	33 (48.5%)
	Moderate	0	3 (4%)	1 (1.5%)	2 (3%)
	Severe	0	0	0	0
Day 3	*No or mild*	6 (9%)	9 (13%)	17 (25%)	34 (50%)
	Moderate	0	1 (1.5%)	0	1 (1.5%)
	Severe	0	0	0	0
Day 4	*No or mild*	6 (9%)	10 (15%)	17 (25%)	33 (48.5%)
	Moderate	0	0	0	2 (3%)
	severe	0	0	0	0

OTHER OUTCOME (3):

Type of analgesics required by patients during study

Groups	Time Interval	No medication	OTC medication	Narcotic medication
Control Group (Calcium hydroxide/Calcipulpe)	4 hrs	*26 (38%)*	*4 (6%)*	*3 (4%)*
Experimental Group (Propolis)		*32 (47%)*	*3 (4%)*	*0*
Total		**58 (85%)**	**7 (10%)**	**3 (4%)**
Control Group (Calcium hydroxide/Calcipulpe)	12 hrs	*27 (40%)*	*4 (6%)*	*2 (3%)*
Experimental Group (Propolis)		*28 (41%)*	*7 (10%)*	*0*
Total		**55 (81%)**	**11 (16%)**	**2 (3%)**
Control Group (Calcium hydroxide/Calcipulpe)	Day 2	*31 (46%)*	*2 (3%)*	*0*
Experimental Group (Propolis)		*31 (46%)*	*4 (6%)*	*0*
Total		**62 (91%)**	**6 (9%)**	**0**
Control Group (Calcium hydroxide/Calcipulpe)	Day 3	*32 (47%)*	*1 (1.5%)*	*0*
Experimental Group (Propolis)		*34 (50%)*	*1 (1.5%)*	*0*
Total		**66 (97%)**	**2 (3%)**	**0**
Control Group (Calcium hydroxide/Calcipulpe)	Day 4	*33 (48.5%)*	*0*	*0*
Experimental Group (Propolis)		*33 (48.5%)*	*2 (3%)*	*0*
Total		**66 (97%)**	**2 (3%)**	**0**

4. Adverse Events

There were no adverse events associated with this trial.